Drug Pricing Legislation Moves Through Senate HELP Committee
June 27, 2019
The U.S. Senate Health, Education, Labor and Pensions Committee voted to pass the Lower Health Care Costs Act on June 26, 2019. The Lower Health Care Costs Act, S. 1895, includes important Society-supported policy priorities including:
The CREATES Act to prohibit brand pharmaceutical manufacturers from using safety programs/restricted access programs as a way to prevent generic or biosimilar manufacturers from purchasing samples to understand how the medication works (and create a generic, lower-cost product).
The FAIR Drug Pricing Act introduced by Senator Tammy Baldwin. The legislation would require drug manufacturers to disclose and provide more information about planned drug price increases, including research and development costs. It was not included in the initial legislation, but Sen. Baldwin brought it up for a vote. It passed by a vote of 16-7 and was included in the larger bill.
There are also provisions in the legislation to protect individuals from surprise medical bills in emergency and non-emergency situations.
The Society looks forward to the bill advancing to the full Senate. Click here
to read Chairman Lamar Alexander’s (R-TN) response to the votes. Click here
to learn more about the Society’s support for policies increasing access to MS medication.
Multiple sclerosis is an unpredictable disease of the central nervous system. Currently there is no cure. Symptoms vary from person to person and may include disabling fatigue, mobility challenges, cognitive changes, and vision issues. An estimated 1 million people live with MS in the United States. Early diagnosis and treatment are critical to minimize disability. Significant progress is being made to achieve a world free of MS.